Trial Profile
International Study of Ezetimibe/Simvastatin Cholesterol Lowering and Major Vascular Events in Chronic Kidney Disease.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Ezetimibe/simvastatin (Primary) ; Simvastatin
- Indications Cardiovascular disorders; Stroke
- Focus Therapeutic Use
- Acronyms SHARP
- Sponsors Merck/Schering-Plough Pharmaceuticals
- 19 Aug 2021 This trial has been discontinued in Spain, as per European Clinical Trials Database record.
- 12 Mar 2014 United Kingdom Clinical Research Network reports accrual to date as 100%
- 31 May 2012 Planned number of patients changed from 9000 to 9438 and additional locations added as reported by United Kingdom Clinical Research Network record.